Review Article
The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas
Table 2
Ongoing clinical trials with rapalogs in patients with NHL.
| | Phase | Locations | Clinical trial gov. number | Additional information |
| | I/II | USA | NCT01076543 | Lenalidomide and Temsirolimus in patients with relapsed or refractory HL or NHL |
| | I/II | USA | NCT00787969 | Rituximab, Cladribe, and Temsirolimus in patients with newly diagnosed MCL |
| | I/II | GERMANY | NCT01078142 | Temsirolimus, Bendamustine, and Rituximab for relapsed FL or MCL (BERT) |
| | I/II | USA | NCT00474929 | Everolimus and sorafenib for relapsed or refractory NHL, HL, or MM |
| | I | Cleveland OH | NCT00671112 | Everolimus plus bortezomibe for relapsed/refractory MCL and other NHL |
| | I/II | USA | NCT00967044 | Panobinostat (LBH589) plus Everolimus (RAD001) in patients with relapsed and refractory Lymphoma |
| | I/II | USA | NCT 101075321 | Everolimus and Lenalidomide in treating patients with relapsed or refractory NHL or HL |
| | I/II | USA | NCT00918333 | Panobinostat and Everolimus in treating patients with recurrent MM, NHL, or HL |
| | II | USA | NCT00869999 | Everolimus plus Rituximab for relapsed/refractory DLBCL |
| | I/II | USA | NCT00704054 | Deferolimus for relapsed/refractory NHL/HL |
|
|
